SPDR Kensho Final Frontiers ETF vs 22nd Century Group Inc — how do they compare? SPDR Kensho Final Frontiers ETF trades at $103.49 (market cap $170.14M), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: SPDR Kensho Final Frontiers ETF is far larger — about 273.7× 22nd Century Group Inc's market cap, and SPDR Kensho Final Frontiers ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Kensho Final Frontiers ETF for 9 Days and 22nd Century Group Inc for 32 Days on average.
| ROKT | XXII | |
|---|---|---|
Market Cap | $170.14M | $621.67K |
Volume | 12,298 | 45,625 |
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $136.68 | $483.00 |
52-Week Low | $72.93 | $0.80 |
Typical Hold Time | 9 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →